Long‑term survival with nivolumab in a patient with renal cell carcinoma: a case report and review of the literature
A heavily pre‑treated patient with metastatic renal cell carcinoma achieved durable complete remission after 48 months of third‑line nivolumab therapy.
Immunotherapy is the standard of care for advanced renal cell carcinoma (RCC). We report a 67‑year‑old man with stage IV ccRCC who, after two prior systemic lines (sunitinib, everolimus), received third‑line nivolumab (240 mg every 2 weeks). Fifteen months later he achieved a partial response; 24 months of treatment led to complete resolution of all pulmonary metastases, and he remains in complete remission after 48 months of therapy.
The case demonstrates that nivolumab can produce long‑term, durable remissions even beyond the second line in heavily pre‑treated metastatic RCC, supporting its use in later clinical settings.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy
- A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions
- EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
- Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics‑based liquid biopsy assay
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)